Omega Therapeutics Looks To Address Disease By Tuning Genomic Regulators

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The newest Flagship spinout says that by drugging insulated genomic domains, it can tune genomic activity without altering DNA to treat and maybe even cure a broad range of diseases.

Binary-code-DNA
Omega hopes to regulate gene expression without altering DNA

Newly launched Omega Therapeutics differentiates itself from other genomic medicine companies by saying that it hopes specifically to target the structures that control gene expression and by tuning these insulated genomic domains (IGDs) come up with a new type of therapeutic that potentially can offer therapeutic benefit, maybe even a cure, in almost any disease that involves dysregulation of the genome.

Based in Cambridge, MA, and launched on 23 September after two years of incubation by Flagship Pioneering, Omega is an...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Start-Ups & SMEs

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Pentixapharm Poised To Make A Splash In The Radiopharmaceuticals Pool

 
• By Kevin Grogan

The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.

Finance Watch: GondolaBio, BridgeBio’s Second Spinout Of 2024, Launches With $300m

 
• By Mandy Jackson

BridgeBio spun out oncology assets in May to focus on rare diseases and now it has sliced off a few rare disease candidates for GondolaBio. Also, Avidity and Kymera closed follow-on offerings that grossed $345.1m and $225m, respectively, and Vandria extended its series A round to $30.7m.

Borealis Seeks Aurora In RNA-Based Drugs For Renal Disease

 
• By Alaric DeArment

With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.